What's in EHL Bio Co., Ltd.'s pipeline?

EHL Bio Co., Ltd. has 2 drugs in our index: 0 marketed, 0 filed, 1 in Phase 3, 0 in Phase 2, 1 in Phase 1.

Which companies overlap with EHL Bio Co., Ltd.'s portfolio?

Top competitors by shared drug class: Aivita Biomedical, Inc., Mesoblast, Inc..

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/ehl-bio-co-ltd.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-14 · How we verify

EHL Bio Co., Ltd. — Portfolio Competitive Intelligence Brief

EHL Bio Co., Ltd. pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
ADSTEM Inj.	ADSTEM Inj.	phase 3	Mesenchymal stem cell therapy		Regenerative Medicine / Orthopedics

Therapeutic area mix

Regenerative Medicine / Orthopedics · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Aivita Biomedical, Inc. · 1 shared drug class
Mesoblast, Inc. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for EHL Bio Co., Ltd.:

Cite this brief

Drug Landscape (2026). EHL Bio Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/ehl-bio-co-ltd. Accessed 2026-05-14.